Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000024164
- Lead Sponsor
- Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Treated with incretin-based therapy 2. Type 1 diabetes or secondary forms of diabetes 3. Renal dysfunction (eGFR <35 ml/min/1.73m2) 4. Hepatic dysfunction (AST and/or ALT >3X upper limit of normal) 5. Malignant neoplasm 6. Severe infection or injury 7. Hypersensitivity to dulaglutide or trelagliptin 8. Pregnant or willing to be pregnant during this study 9. Unable to obtain informed consent to this study 10. Unable to maintain compliance during this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method